ES2684950T3 - Usos de inmunoconjugados dirigidos a CD138 - Google Patents
Usos de inmunoconjugados dirigidos a CD138 Download PDFInfo
- Publication number
- ES2684950T3 ES2684950T3 ES12798723.8T ES12798723T ES2684950T3 ES 2684950 T3 ES2684950 T3 ES 2684950T3 ES 12798723 T ES12798723 T ES 12798723T ES 2684950 T3 ES2684950 T3 ES 2684950T3
- Authority
- ES
- Spain
- Prior art keywords
- dose
- carcinoma
- immunoconjugate
- seq
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Un inmunoconjugado para su uso en el tratamiento de una enfermedad asociada a células diana que expresan CD138 en un sujeto humano, donde el inmunoconjugado comprende al menos un anticuerpo dirigido a diana de ingeniería que marca como diana células que expresan CD138 y al menos una molécula efectora, donde dicho anticuerpo dirigido a diana de ingeniería se fija funcionalmente a dicha molécula efectora para formar dicho inmunoconjugado, donde preferentemente al menos parte del anticuerpo dirigido a diana de ingeniería confiere propiedades de isotipo IgG4, donde la molécula efectora es al menos un maitansinoide, donde el anticuerpo dirigido a diana de ingeniería comprende: (i) una región variable de cadena pesada CDR1 que comprende los restos de aminoácidos 31 a 35 de SEQ ID NO: 1, una región variable de cadena pesada CDR2 que comprende los restos de aminoácidos 51 a 68 de SEQ ID NO: 1 y una región variable de cadena pesada CDR3 que comprende los restos de aminoácidos 99 a 111 de SEQ ID NO: 1; y (ii) una región variable de cadena ligera CDR1 que comprende los restos de aminoácidos 24 a 34 de SEQ ID NO: 2, una región variable de cadena ligera CDR2 que comprende los restos de aminoácidos 50 a 56 de SEQ ID NO: 2 y una región variable de cadena ligera CDR3 que comprende los restos de aminoácidos 89 a 97 de SEQ ID NO: 2; donde el inmunoconjugado ha de administrarse en un régimen de múltiples dosis, donde la dosis de agregado a administrarse dentro de un ciclo de tratamiento activo es una dosis tolerable máxima agregada (AMTD) o una fracción de AMTD y donde dicha AMTD y/o dicha fracción excede la dosis que resulta en toxicidad limitante de dosis (DLT) cuando el inmunoconjugado se administra como una dosis única, incluyendo como parte de un régimen de dosis única múltiple dentro de dicho ciclo de tratamiento activo y/o excede la dosis tolerable máxima (MTD) cuando el inmunoconjugado se administra como una sola dosis, incluyendo como parte de un régimen de dosis única múltiple dentro de dicho ciclo de tratamiento activo, donde la dosis tolerable máxima agregada es al menos 240 mg/m2, preferentemente 300 mg/m2, preferentemente 360 mg/m2, preferentemente 420 mg/m2, donde la dosis que resulta en dicha toxicidad limitante de dosis es 200 mg/m2 y/o la dosis tolerable máxima al menos 160 mg/m2 o al menos 180 mg/m2, donde el inmunoconjugado ha de administrarse en un ciclo de tratamiento activo de 21 días, al menos tres veces dentro de dichos 21 días, donde el ciclo de tratamiento activo incluye la administración del inmunoconjugado realizándose al menos una vez a la semana, donde la enfermedad asociada a las células diana que expresan CD138 es mieloma múltiple, carcinoma de células renales, cáncer de endometrio, cáncer cervical, adenocarcinoma de próstata, carcinoma pancreático, cáncer gástrico, cáncer de vejiga, carcinoma mamario, hepato-carcinoma, carcinoma colorrectal, carcinoma de colon, carcinoma de células escamosas, cáncer de pulmón, linfoma no Hodgkiniano, carcinoma de timo, carcinoma de útero, carcinoma urinario o carcinoma de ovario.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161568640P | 2011-12-08 | 2011-12-08 | |
US201161568640P | 2011-12-08 | ||
US201261722367P | 2012-11-05 | 2012-11-05 | |
US201261722367P | 2012-11-05 | ||
PCT/EP2012/074867 WO2013083817A1 (en) | 2011-12-08 | 2012-12-07 | Uses of immunoconjugates targeting cd138 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2684950T3 true ES2684950T3 (es) | 2018-10-05 |
Family
ID=47326154
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES12798723.8T Active ES2684950T3 (es) | 2011-12-08 | 2012-12-07 | Usos de inmunoconjugados dirigidos a CD138 |
Country Status (15)
Country | Link |
---|---|
US (2) | US10117932B2 (es) |
EP (1) | EP2788030B1 (es) |
JP (1) | JP6218746B2 (es) |
KR (1) | KR20140100571A (es) |
CN (1) | CN104302324A (es) |
AU (1) | AU2012372140B9 (es) |
BR (1) | BR112014013694A2 (es) |
CA (1) | CA2858133A1 (es) |
ES (1) | ES2684950T3 (es) |
HK (1) | HK1203053A1 (es) |
IL (1) | IL232991A0 (es) |
MX (1) | MX358680B (es) |
RU (1) | RU2632108C2 (es) |
SG (1) | SG11201402887SA (es) |
WO (1) | WO2013083817A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI541022B (zh) * | 2013-12-18 | 2016-07-11 | 應克隆公司 | 針對纖維母細胞生長因子受體-3(fgfr3)之化合物及治療方法 |
US11041021B2 (en) | 2014-05-23 | 2021-06-22 | University Of Florida Research Foundation, Incorporated | Car based immunotherapy |
US10647778B2 (en) * | 2015-02-09 | 2020-05-12 | University Of Florida Research Foundation, Incorporated | Bi-specific chimeric antigen receptor and uses thereof |
EP3259352A4 (en) | 2015-02-19 | 2018-12-05 | University of Florida Research Foundation, Inc. | Chimeric antigen receptors and uses thereof |
TW201711702A (zh) * | 2015-06-04 | 2017-04-01 | 應克隆公司 | 使用針對纖維母細胞生長因子受體3(fgfr3)之化合物的療法 |
WO2017190096A1 (en) | 2016-04-29 | 2017-11-02 | University Of Florida Research Foundation Incorporated | Chimeric antigen receptors and uses thereof |
WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
WO2019070726A1 (en) | 2017-10-02 | 2019-04-11 | Visterra, Inc. | CD73 BINDING ANTIBODY MOLECULES AND USES THEREOF |
AR116563A1 (es) * | 2018-10-02 | 2021-05-19 | Mitsubishi Tanabe Pharma Corp | Agentes de unión biespecíficos dirigidos a sindecano-1 y receptor de factor de crecimiento de fibroblastos |
WO2024181570A1 (ja) * | 2023-03-02 | 2024-09-06 | 大鵬薬品工業株式会社 | 抗cd138抗体を含む抗体薬物複合体 |
Family Cites Families (103)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3896111A (en) | 1973-02-20 | 1975-07-22 | Research Corp | Ansa macrolides |
US4151042A (en) | 1977-03-31 | 1979-04-24 | Takeda Chemical Industries, Ltd. | Method for producing maytansinol and its derivatives |
US4169888A (en) | 1977-10-17 | 1979-10-02 | The Upjohn Company | Composition of matter and process |
US4137230A (en) | 1977-11-14 | 1979-01-30 | Takeda Chemical Industries, Ltd. | Method for the production of maytansinoids |
US4265814A (en) | 1978-03-24 | 1981-05-05 | Takeda Chemical Industries | Matansinol 3-n-hexadecanoate |
US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
JPS5562090A (en) | 1978-10-27 | 1980-05-10 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS55164687A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
US4256746A (en) | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
JPS5566585A (en) | 1978-11-14 | 1980-05-20 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS55102583A (en) | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
JPS55164685A (en) | 1979-06-08 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS55164686A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
US4309428A (en) | 1979-07-30 | 1982-01-05 | Takeda Chemical Industries, Ltd. | Maytansinoids |
JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
JPS5645485A (en) | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
EP0028683A1 (en) | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotic C-15003 PHO and production thereof |
US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
WO1982001188A1 (en) | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | 4,5-deoxymaytansinoide compounds and process for preparing same |
US4315929A (en) | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
US4313946A (en) | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
US4563304A (en) | 1981-02-27 | 1986-01-07 | Pharmacia Fine Chemicals Ab | Pyridine compounds modifying proteins, polypeptides or polysaccharides |
JPS57192389A (en) | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
US4761111A (en) | 1981-09-18 | 1988-08-02 | Brown Andrew M | Automobile lifting and towing equipment |
US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
US4418064A (en) | 1982-09-29 | 1983-11-29 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids: treflorine, trenudine, and N-methyltrenudone |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5034223A (en) | 1986-10-09 | 1991-07-23 | Neorx Corporation | Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof |
US5053394A (en) | 1988-09-21 | 1991-10-01 | American Cyanamid Company | Targeted forms of methyltrithio antitumor agents |
US5612016A (en) | 1988-04-01 | 1997-03-18 | Immunomedics, Inc. | Conjugates of antibodies and bifunctional ligands |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
EP0777964B1 (en) | 1989-08-30 | 2001-11-14 | Kynoch Agrochemicals (Proprietary) Limited | Preparation of a dosage device |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
EP0527189A1 (en) | 1990-04-25 | 1993-02-17 | PHARMACIA & UPJOHN COMPANY | Novel cc-1065 analogs |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
US5998656A (en) | 1991-09-23 | 1999-12-07 | Florida State University | C10 tricyclic taxanes |
US6080777A (en) | 1992-01-31 | 2000-06-27 | The Trustees Of Columbia University In The City Of New York | Taxol as a radiation sensitizer |
US5200534A (en) | 1992-03-13 | 1993-04-06 | University Of Florida | Process for the preparation of taxol and 10-deacetyltaxol |
DE69231123T2 (de) | 1992-03-25 | 2001-02-15 | Immunogen Inc | Konjugaten von Zell-bindender Mittel und Derivaten von CC-1065 |
US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
US5703247A (en) | 1993-03-11 | 1997-12-30 | Virginia Tech Intellectual Properties, Inc. | 2-Debenzoyl-2-acyl taxol derivatives and methods for making same |
US5475011A (en) | 1993-03-26 | 1995-12-12 | The Research Foundation Of State University Of New York | Anti-tumor compounds, pharmaceutical compositions, methods for preparation thereof and for treatment |
US6740734B1 (en) | 1994-01-14 | 2004-05-25 | Biovitrum Ab | Bacterial receptor structures |
SE9400088D0 (sv) | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
US5763477A (en) | 1994-07-22 | 1998-06-09 | Dr. Reddy's Research Foundation | Taxane derivatives from 14-β-hydroxy-10 deacetylbaccatin III |
JPH11501931A (ja) | 1995-03-10 | 1999-02-16 | ハウザー,インコーポレイテッド | セファロマンニンエポキシド、その類似体およびそれらの製造方法 |
ATE390933T1 (de) | 1995-04-27 | 2008-04-15 | Amgen Fremont Inc | Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8 |
AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
JP2002514895A (ja) | 1995-09-28 | 2002-05-21 | アレクション、ファーマスーティカルズ、インコーポレーテッド | ブタ細胞相互作用タンパク質 |
US6001358A (en) | 1995-11-07 | 1999-12-14 | Idec Pharmaceuticals Corporation | Humanized antibodies to human gp39, compositions containing thereof |
WO1997049428A1 (fr) | 1996-06-27 | 1997-12-31 | Chugai Seiyaku Kabushiki Kaisha | Remedes contre les myelomes a utiliser en combinaison avec des agents anti-tumoraux a base d'azote de la moutarde |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
AU5702298A (en) | 1996-12-03 | 1998-06-29 | Abgenix, Inc. | Transgenic mammals having human Ig loci including plural VH and VK regions nd antibodies produced therefrom |
SI0970126T1 (en) | 1997-04-14 | 2001-08-31 | Micromet Ag | Novel method for the production of antihuman antigen receptors and uses thereof |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
US6962702B2 (en) | 1998-06-22 | 2005-11-08 | Immunomedics Inc. | Production and use of novel peptide-based agents for use with bi-specific antibodies |
US6087362A (en) | 1999-03-16 | 2000-07-11 | Pentech Pharmaceuticals, Inc. | Apomorphine and sildenafil composition |
US6635677B2 (en) | 1999-08-13 | 2003-10-21 | Case Western Reserve University | Methoxyamine combinations in the treatment of cancer |
WO2001024763A2 (en) | 1999-10-01 | 2001-04-12 | Immunogen, Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
ATE349438T1 (de) | 1999-11-24 | 2007-01-15 | Immunogen Inc | Cytotoxische wirkstoffe enthaltend taxane und deren therapeutische anwendung |
US6333410B1 (en) | 2000-08-18 | 2001-12-25 | Immunogen, Inc. | Process for the preparation and purification of thiol-containing maytansinoids |
US7229960B2 (en) | 2000-11-03 | 2007-06-12 | University Of Vermont And State Agricultural College | Methods and compositions for inhibiting GRB7 |
US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
NZ592087A (en) | 2001-08-03 | 2012-11-30 | Roche Glycart Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
US20030109682A1 (en) | 2001-09-07 | 2003-06-12 | Daniel Santi | Maytansines and maytansine conjugates |
US6716821B2 (en) | 2001-12-21 | 2004-04-06 | Immunogen Inc. | Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same |
US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
US6534660B1 (en) | 2002-04-05 | 2003-03-18 | Immunogen, Inc. | CC-1065 analog synthesis |
US6756397B2 (en) | 2002-04-05 | 2004-06-29 | Immunogen, Inc. | Prodrugs of CC-1065 analogs |
WO2003090781A1 (en) | 2002-04-23 | 2003-11-06 | Meir Strahilevitz | Methods and devices for targeting a site in a mammal and for removing species from a mammal |
PT3127553T (pt) | 2002-05-02 | 2022-01-24 | Wyeth Holdings Llc | Conjugados de derivado da caliqueamicina - transportador |
US6596757B1 (en) | 2002-05-14 | 2003-07-22 | Immunogen Inc. | Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use |
US7390898B2 (en) | 2002-08-02 | 2008-06-24 | Immunogen Inc. | Cytotoxic agents containing novel potent taxanes and their therapeutic use |
AU2003259163B2 (en) | 2002-08-16 | 2008-07-03 | Immunogen, Inc. | Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs |
US20040126379A1 (en) | 2002-08-21 | 2004-07-01 | Boehringer Ingelheim International Gmbh | Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents |
EP2248892B1 (en) | 2003-01-22 | 2015-04-22 | Roche Glycart AG | Fusion constructs and use of same to produce antibodies with increased FC receptor binding affinity and effector function |
CA2525029A1 (en) | 2003-05-02 | 2004-11-18 | Health Research, Inc. | Use of jag2 expression in diagnosis of plasma cell disorders |
US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
ATE496944T1 (de) | 2003-07-21 | 2011-02-15 | Immunogen Inc | Ca6-antigenspezifisches zytotoxisches konjugat und verfahren zu dessen anwendung |
AU2005249490B2 (en) | 2004-06-01 | 2010-07-29 | Genentech, Inc. | Antibody drug conjugates and methods |
US20060045877A1 (en) | 2004-08-30 | 2006-03-02 | Goldmakher Viktor S | Immunoconjugates targeting syndecan-1 expressing cells and use thereof |
CN101218256B (zh) | 2005-03-23 | 2017-04-19 | 根马布股份公司 | 用于治疗多发性骨髓瘤的cd38抗体 |
JP2008538365A (ja) | 2005-04-15 | 2008-10-23 | イミュノジェン・インコーポレーテッド | 腫瘍内の不均一または混合細胞集団を排除する方法 |
EP1963370A1 (en) | 2005-12-06 | 2008-09-03 | Domantis Limited | Bispecific ligands with binding specificity to cell surface targets and methods of use therefor |
EP1999149A4 (en) | 2006-03-28 | 2010-01-20 | Biogen Idec Inc | ANTI-IGF-1R ANTIBODIES AND USES THEREOF |
EP2015772A2 (de) | 2006-05-03 | 2009-01-21 | Elke Pogge Von Strandmann | Mittel zur behandlung von malignen erkrankungen |
PL2242772T3 (pl) | 2007-12-26 | 2015-05-29 | Biotest Ag | Immunokonjugaty nakierowane na CD138 i ich zastosowanie |
AR069979A1 (es) | 2007-12-26 | 2010-03-03 | Biotest Ag | Metodo para disminuir los efectos secundarios citotoxicos y mejorar la eficacia de los inmunoconjugados |
PT2238168E (pt) * | 2007-12-26 | 2014-07-18 | Biotest Ag | Agentes visando cd138 e suas utilizações |
ES2543201T3 (es) | 2007-12-26 | 2015-08-17 | Biotest Ag | Métodos y agentes que mejoran la dirección a las células tumorales que expresan CD138 |
KR20110028450A (ko) | 2008-06-16 | 2011-03-18 | 이뮤노젠 아이엔씨 | 새로운 상승 효과 |
MX345953B (es) * | 2009-05-06 | 2017-01-27 | Biotest Ag | Usos de inmunoconjugados dirigidos a cd138. |
-
2012
- 2012-12-07 CN CN201280069240.6A patent/CN104302324A/zh active Pending
- 2012-12-07 BR BR112014013694A patent/BR112014013694A2/pt not_active Application Discontinuation
- 2012-12-07 JP JP2014545298A patent/JP6218746B2/ja not_active Expired - Fee Related
- 2012-12-07 WO PCT/EP2012/074867 patent/WO2013083817A1/en active Application Filing
- 2012-12-07 RU RU2014127298A patent/RU2632108C2/ru not_active IP Right Cessation
- 2012-12-07 CA CA2858133A patent/CA2858133A1/en not_active Abandoned
- 2012-12-07 MX MX2014006770A patent/MX358680B/es active IP Right Grant
- 2012-12-07 EP EP12798723.8A patent/EP2788030B1/en not_active Not-in-force
- 2012-12-07 SG SG11201402887SA patent/SG11201402887SA/en unknown
- 2012-12-07 US US13/708,014 patent/US10117932B2/en not_active Expired - Fee Related
- 2012-12-07 AU AU2012372140A patent/AU2012372140B9/en not_active Ceased
- 2012-12-07 ES ES12798723.8T patent/ES2684950T3/es active Active
- 2012-12-07 KR KR1020147018841A patent/KR20140100571A/ko not_active Application Discontinuation
-
2014
- 2014-06-05 IL IL232991A patent/IL232991A0/en unknown
-
2015
- 2015-04-13 HK HK15103595.6A patent/HK1203053A1/xx not_active IP Right Cessation
-
2018
- 2018-09-24 US US16/139,379 patent/US20190117770A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
NZ626680A (en) | 2016-05-27 |
US20140010828A1 (en) | 2014-01-09 |
SG11201402887SA (en) | 2014-07-30 |
WO2013083817A1 (en) | 2013-06-13 |
EP2788030B1 (en) | 2018-06-20 |
AU2012372140A1 (en) | 2013-09-26 |
US20190117770A1 (en) | 2019-04-25 |
HK1203053A1 (en) | 2015-10-16 |
RU2014127298A (ru) | 2016-01-27 |
JP6218746B2 (ja) | 2017-10-25 |
IL232991A0 (en) | 2014-07-31 |
JP2015500822A (ja) | 2015-01-08 |
MX2014006770A (es) | 2014-10-17 |
US10117932B2 (en) | 2018-11-06 |
AU2012372140B9 (en) | 2015-10-15 |
BR112014013694A2 (pt) | 2017-06-13 |
EP2788030A1 (en) | 2014-10-15 |
CN104302324A (zh) | 2015-01-21 |
RU2632108C2 (ru) | 2017-10-02 |
CA2858133A1 (en) | 2013-06-13 |
KR20140100571A (ko) | 2014-08-14 |
MX358680B (es) | 2018-08-31 |
AU2012372140B2 (en) | 2015-09-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2684950T3 (es) | Usos de inmunoconjugados dirigidos a CD138 | |
EA201390642A1 (ru) | Цитотоксические агенты, содержащие новые производные анзамитоцина | |
CY1121148T1 (el) | Παραγοντες συνδεσης vegf/dll4 και χρησεις αυτων | |
MX2022006107A (es) | Metodos y composiciones para dosificacion en terapia celular adoptiva. | |
AR085747A1 (es) | Conjugados de anticuerpo-farmaco contra el antigeno 5t4 expresado en celulas iniciadoras del tumor | |
CL2012002326A1 (es) | Uso de una combinación de por lo menos un agente quimioterapéutico y una cantidad efectiva de un anticuerpo anti-vegf (factor de crecimiento endotelial vascular), porque sirve para preparar un medicamento útil en el tratamiento de cáncer ovárico; y su kit para tratar el cáncer ovárico sin tratamiento anterior en una paciente humana. | |
WO2018157171A3 (en) | Compositions, articles of manufacture and methods related to dosing in cell therapy | |
NZ596807A (en) | Uses of immunoconjugates targeting cd138 | |
EA201792652A3 (ru) | Новые производные майтанзиноида с пептидным линкером и их конъюгаты | |
CO7101193A2 (es) | Anticuerpo anti-epirregulina humanizado y agente terapéutico con el cancer que comprende dicho anticuerpo como ingrediente activo | |
AU2015219495B2 (en) | Disease therapy by inducing immune response to Trop-2 expressing cells | |
MX348581B (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer. | |
EA201692530A1 (ru) | Цитотоксические пептиды и их конъюгаты | |
EA201201186A1 (ru) | ИСПОЛЬЗОВАНИЕ ErbB3 ИНГИБИТОРОВ В ЛЕЧЕНИИ ТРИЖДЫ НЕГАТИВНОГО И БАЗАЛЬНО-ПОДОБНОГО ВИДОВ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ | |
AR059982A1 (es) | Terapia tumoral con un anticuerpo contra el factor de crecimiento endotelial vascular y un anticuerpo contra el receptor del factor de crecimiento epitelial tipo 2 humano | |
NZ631405A (en) | Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer | |
RU2016129894A (ru) | Ковалентно связанные конъюгаты хеликар-антитело против хеликара и их применения | |
ES2721378T3 (es) | Anticuerpos anti-TLR4 y métodos de uso de los mismos | |
EA201690321A1 (ru) | Применение иммуноконъюгата антитела к muc1 и майтанзиноида для лечения солидных опухолей | |
CY1121973T1 (el) | Θεραπεια φαρμακευτικα ανθεκτικου καρκινου η οποια στοχευει καρκινικα βλαστοκυτταρα | |
CY1121667T1 (el) | Παραγοντες για θεραπεια τριπλα αρνητικου καρκινου μαστου | |
CY1126032T1 (el) | Συζευγματα αντισωματος-φαρμακου που στοχευουν uparap | |
AU2012253610A8 (en) | Compositions and methods for treating cancer | |
NZ703786A (en) | Fgfr1 extracellular domain combination therapies | |
PE20161413A1 (es) | Conjugados de anticuerpo anti-efna4-farmaco |